A Phase 1, Open-label, Functional Imaging Study to Assess Whether CC-90011 Reverses the Castration Resistance Due to Lineage Switch in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Have Failed Enzalutamide as Last Prior Therapy, Followed by a Dose Finding Study of CC-90011 Combined With Abiraterone and Prednisone
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Abiraterone (Primary) ; Prednisone (Primary) ; Pulrodemstat (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 11 Sep 2023 Status changed from active, no longer recruiting to completed.
- 26 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2022 Planned End Date changed from 15 Aug 2024 to 18 Mar 2025.